Wrzodziejące zapalenie jelita grubego: badanie fazy II leku LY4268989
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Badania kliniczne, które rekrutują lub wkrótce zaczną rekrutację w ośrodkach w mieście Katowice. Najwięcej badań dotyczy: nowotwór, choroba sercowo-naczyniowa, chłoniak, choroba układu pokarmowego.
466 badań: 429 rekrutuje, 37 wkrótce zacznie.
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor…
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor…
ShockFast Intravascular Lithotripsy Device for Treatment of Calcified Coronary Lesions
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Ravulizumab Outcomes in Polish Patients With aHUS
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)…
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
HOVON 181 AML: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed…
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
Polish Registry of Percutaneous Coronary Intervention for Chronic Total Occlusions
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
A Study of LAD603 in Adults With Alopecia Areata
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Confirmatory Clinical Study in Active Ulcerative Colitis
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy…
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a…
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 18 listopada 2026.